At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,272 enrolled
Drug / intervention
Plecanatidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Long Term Safety and Tolerability Study of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
In Brief
A Phase 3 clinical trial evaluating Plecanatide for Irritable Bowel Syndrome. Completed, enrolled 2,272 participants across 204 sites.
Detailed Summary
Multi-center, open-label, long-term safety study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedMar 2016
Primary CompletionMay 2017
Study CompletionJun 2017
TodayJul 2026
First PostedMar 11, 2016
Enrollment StartJan 1, 2016
Primary CompletionMay 1, 2017
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.3 years ago
Interventions
Plecanatidedrug